Phase IV EORTC Quality of Life Module for Patients With Chronic Myeloid Leukemia
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Blood Cancer, Blood Cancer, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 3/23/2019 |
| Start Date: | August 3, 2017 |
| End Date: | December 2019 |
An International Field Study for the Reliability and Validity of the Phase IV EORTC Quality of Life Module for Patients With Chronic Myeloid Leukemia (EORTC QLQ-CML24)
The objective of this study is to test the scale structure, reliability, validity and
responsiveness to change of the QLQ-CML24 in conjuction with the QLQ-C30 for patients
diagnosed with CML, and to investigate longitudinal relationship between satisfaction with
information provision and QoL outcomes.
responsiveness to change of the QLQ-CML24 in conjuction with the QLQ-C30 for patients
diagnosed with CML, and to investigate longitudinal relationship between satisfaction with
information provision and QoL outcomes.
Inclusion Criteria:
- Above 18 years of age.
- Patient with confirmed diagnosis of Philadelphia chromosome positive and/or BCR-ABL
positive chronic myeloid leukemia (CML).
- Written informed consent.
- Patients enrolled in investigational drug-trials or other type of clinical trials are
also eligible.
Exclusion Criteria:
- Patients with a psychiatric condition or major cognitive impairment (as evaluated by
their treating physician) that would hinder completion of self-reported health-related
QoL questionnaires.
- Patients who are unable to speak and read the language of the questionnaire.
We found this trial at
2
sites
Click here to add this to my saved trials
1365 Clifton Road
Emory, Georgia 30322
Emory, Georgia 30322
Principal Investigator: Vamsi Kota
Click here to add this to my saved trials